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Abstract: Cancer patients receiving chemotherapy often develop mucositis as a direct 
result of their treatment. Recently, the intestinal microbiota has attracted significant 
attention in the investigation of the pathobiology of mucositis, with a number of studies 
investigating the effects of chemotherapeutic agents on the microbiota. With significant 
effects on the intestinal microbiota occurring following the administration of 
chemotherapy, there is now interest surrounding the downstream pathological effects that 
may be associated with the altered intestinal ecology. This review seeks to identify links 
between signalling pathways previously demonstrated to have a role in the development of 
mucositis, and the altered intestinal microbiota. 
Keywords: intestine; microbiota; chemotherapy; mucositis; toll like receptors; mitogen 
activated protein kinase 
 
1. Introduction 
Cancer patients receiving chemotherapy often develop mucositis as a direct result of their  
treatment. It is a major oncological problem reported in approximately 40% of patients undergoing 
standard dose chemotherapy and in almost all patients receiving high dose chemotherapy and stem cell 
transplantation. This condition was originally thought to be limited to the mucous membranes 
throughout the alimentary tract, although more recent research has indicated that other tissue layers 
and the luminal contents and its inhabitants are likely to be involved [1]. The entire alimentary tract 
(mouth to anus) is affected. Clinical symptoms of intestinal mucositis are the result of ulceration,  
and include abdominal pain, nausea, vomiting, bloating, diarrhoea, constipation, and subsequent 
weight loss [1].  
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2. Pathobiology of Mucositis 
Cytotoxic chemotherapy is a common treatment for malignancies which has been in use for 
approximately 50 years [2]. It can cause functional and structural changes to the gastrointestinal tract 
(GIT) [3]. Common gastrointestinal symptoms following chemotherapy include heartburn, abdominal 
pain, diarrhoea (and constipation), bloating and nausea [4]. These symptoms arise as the result of the 
damage caused by chemotherapy agents [5]. Abdominal pain is caused by the extensive damage 
occurring in the small intestine. Diarrhoea and constipation are thought to be caused by the alteration 
in absorptive functions of cells, goblet cell and mucin distribution and composition, and bacterial 
interactions with these cells and metabolites of the drugs themselves [6,7]. Cytotoxic drugs are known 
to act by inducing apoptosis in cancer; apoptosis is also induced in the GIT [8–10]. There are limited 
ways the mucosa and underlying layers of the GIT can respond to damage. These are the same ways 
that chemotherapy causes damage to the GIT, including cell death, which leads to villous atrophy and 
crypt ablation in the small intestine, and crypt ablation in the large intestine [4]. 
The currently accepted hypothesis for the development of alimentary mucositis (AM) suggests  
that there are five intertwined phases, namely; (1) initiation; (2) up-regulation and generation of 
messenger signals; (3) signal amplification; (4) ulceration and (5) healing [11–13]. This current 
hypothesis has been supported in both animal and human studies [14–19]. Of particular interest is the 
ulceration phase, where pathological evidence of mucositis is observed, both macroscopically (ulcers) 
and microscopically (cell changes). Some of these changes observed in animal models and in humans 
include histological damage [1,10,16,20] and mucin secretion during mucositis [16,21–23]. 
3. Possible Roles for Microbiota in the Pathobiology of Chemotherapy-Induced Mucositis 
Recently, the microbiota has attracted significant attention in the investigation of the pathobiology 
of mucositis. The role of the microbiota in the development of chemotherapy induced mucositis has been 
investigated on a number of levels, including roles in the above-mentioned 5-phase model of mucositis 
developed by Sonis [12,13,24]. This model is the benchmark model for the pathobiology of mucositis 
and is a benchmark for current investigative studies in the field. Breaking this model down, roles for 
microbiota and associated host-microbe responses can be attributed to the different phases of the model. 
3.1. Initiation and Generation of Reactive Oxygen Species 
Chemotherapy treatment causes damage to all tissue types in the gastrointestinal tract. Chemotherapy 
agents act on and damage crypt cells directly by causing DNA damage or indirectly through production 
of reactive oxygen species (ROS) (free radicals) and ceramide synthesis [12,13,24]. Reduction of 
oxygen via univalent reduction results in the formation of superoxide radical, followed by hydrogen 
peroxide [25]. Superoxide radical is impermeative, however hydrogen peroxide is isoelectric with 
water and can diffuse freely across the cell membrane. In the intestine, both host and bacterial cells 
usually contain enzymes to protect vital biological molecules (such as DNA, proteins, and lipids) 
against attack from ROS [25]. Intestinal oxygenation is affected by the production of ROS, and this in 
turn will have effects on the bacterial symbionts present in the intestine [25]. Recent studies have 
suggested that the environmental conditions (e.g., oxygen levels) play a role in determining the 
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composition of intestinal bacterial communities [26]. Inversions of bacterial communities have been 
observed in patients with ileostomies, with increases seen in Lactobacilli and Enterobacteriaceae 
(aerotolerant bacteria) at the expense of anaerobes [26]. Normal proportions were restored following 
closure of the ileostomies, demonstrating the adaptability of the microbiota under the influence of oxygen.  
Under homeostatic conditions, characterised by a state of low-grade inflammation in the intestine, 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) oxidase (NOX)/dual oxidase (DUOX) 
enzymes appear to be responsible for the production and tight control of ROS production [27,28]. 
However, with excessive production of free radicals during the initiation phase of chemotherapy-induced 
mucositis, enzymatic supply responsible for this tight control of ROS may become exhausted, allowing 
ROS access to these vital molecules, allowing damage to cells, tissues and blood vessels. Of greater 
concern is the initiation of downstream biological events. 
3.2. Nuclear Factor Kappa B (NFκB) Up-Regulation, Message Generation, and Amplification 
Chemotherapy agents can also activate the transcription factor nuclear factor kappa B (NFκB),  
both directly and through the generation of ROS, which in turn up-regulates approximately 200 genes, 
(most notably pro-inflammatory cytokines) often resulting in feedback loops to create more  
damage [12,13,24]. The intestinal microbiota may play a key role in this phase through the activation 
of toll like receptor (TLR) signalling [29,30]. The constant residence of microbes in the intestine 
results in constant exposure to TLR ligands, including peptidoglycans, lipopolysaccharide (LPS) and 
bacterial DNA. These ligands result in a state of low-grade inflammation [31–33], and the bacteria are 
processed so parts can be transported intracellularly, allowing binding to NOD receptors. Activation of 
NOD receptors is believed to modulate the inflammatory response activated by TLR activation [34]. 
The most likely TLRs involved in intestinal mucositis are TLR2, TLR4, TLR5 and TLR9. Once 
activated by intestinal microbiota, TLRs can also up-regulate NFκB through complex signalling 
pathways [35], further compounding the inflammatory response through the generation and 
amplification of tumour necrosis factor (TNF)-α, IL-1β, and IL-6 [13]. Further highlighting the 
importance of microbial balance in the intestine is the evidence that commensal microbiota can also 
decrease NFκB activation [36,37]. Commensal species of bacteria, Bifidobacterium infantis and 
Bacteroides thetaiotaomicron have both been shown to decrease NFκB activation, with subsequent 
decreases in endotoxin levels, and plasma pro-inflammatory cytokine levels [36–38]. Another 
commensal bacterium thought to decrease NFκB activation is Faecalibacterium prausnitzii [39].  
F. prausnitzii is able to secrete a substance inducing the production of IL-10, an anti-inflammatory 
cytokine, resulting in decreased NFκB activation and attenuated inflammation [39]. These findings 
may suggest that careful regulation of the commensal microbiota following chemotherapy may assist 
in sustaining intestinal structural integrity through a reduced inflammatory response. However, further 
investigation into the role of the commensal microbiota in maintaining intestinal structural integrity is 
required to confirm this hypothesis. 
4. Mucous Mechanisms of Modulating Microbiota 
Intestinal mucins are high molecular weight glycoproteins secreted by goblet cells. Previous studies 
have demonstrated significant effects on intestinal mucins. Mucins play a key role in protecting the 
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integrity of both the intestinal tissue, and the intestinal microbiota [40]. Their structure provides attachment 
sites and nutrients for microbes, whilst simultaneously protecting the mucosa from bacterial overgrowth 
and/or penetration [41]. Another key role is to protect the epithelium from digestion by bacterial 
enzymes, by acting as substrates for enzymes such as α-galactosidase, β-N-acetylgalactosaminidase, 
sialidase, β-glucuronidase, blood group degrading enzymes, and proteases [41]. 
Goblet cells rapidly discharge most or all of their stored intracellular mucin in response to a variety 
of stimuli, including cholinergic stimuli, intestinal anaphylaxis, and chemical or physical irritation [41]. 
The differential secretion of mucins from surface epithelium and glands may provide a mechanism for 
the modulation of the protective mucous layer in response to acid secretion, or the presence of bacteria 
or noxious agents in the lumen [42]. Interleukin (IL)-1, IL-4, IL-6, IL-9, and tumor necrosis factor 
alpha (TNF)-α have been shown to stimulate the rapid release of mucin from cells [43]. Other 
bioactive factors from intestinal bacteria or host immune cells may also affect the goblet cell dynamics 
and mucous layer. Further intertwined involvement of the intestinal microbiota, mucins and 
interleukins has also been demonstrated by a number of other earlier studies [43–46]. In the same 
animal model of mucositis, the intestinal microbiota has been shown to be significantly altered, with 
decreases in commensal bacteria and increases in potential pathogens [47]. This has been shown to 
occur at similar times during the development of mucositis to significant increases in the cavitation of 
goblet cells in the colon [23]. Intertwining with these events is increases in both tissue levels and 
circulating serum levels of TNF, IL-1β, and IL-6 [19,20]. 
5. Effects of Chemotherapy 
5.1. Effects of Chemotherapy on the Intestinal Microbiota 
Several studies have demonstrated the effects of chemotherapy agents on the intestinal  
microbiota [48]. One of the most investigated agents is irinotecan, due to the involvement of intestinal 
microbiota in its metabolism [6]. Irinotecan (used to treat a variety of solid tumours) is a 
topoisomerase-I inhibitor, converted to active and toxic metabolite SN-38, before being further 
metabolised to non-toxic metabolite SN-38 glucuronide (SN-38G) [6]. This molecule is excreted into 
the gastrointestinal tract where it becomes susceptible to processing by bacterial enzymes. Intestinal 
microbes produce the enzyme β-glucuronidase, which can cleave the glucuronide molecule from the 
less toxic metabolite of irinotecan, rendering it re-activated and toxic [6]. The effects on the intestinal 
microbiota caused by irinotecan have been considered important due to this involvement in the drug’s 
metabolism and potentially compounded toxicities. Studies using single dose (200 mg/kg) irinotecan in 
Dark Agouti (DA) rats and quantitative 16S rRNA real time PCR have shown significant (p < 0.05) 
increases in E. coli (a β-glucuronidase producing bacterium) following its administration, with 
significant decreases (p < 0.05) in Bifidobacterium spp. and Lactobacillus spp., which do not produce 
β-glucuronidase [14,21,47]. These changes were also associated with an increased staining intensity 
for β-glucuronidase in the intestine [47]. A more recent study by Lin and colleagues in 2012 has  
also demonstrated variations in intestinal microbes using molecular techniques [49]. Irinotecan  
(3 × 125 mg/kg) was shown to increase the Clostridium cluster XI and Enterobacteriacaea groups of 
bacteria, both of which harbour opportunistic pathogens. In addition, studies looking at gene 
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expression analysis using microarray techniques have also shown members of the TLR signalling 
pathway to be overwhelmingly upregulated [50,51]. These findings may suggest that TLR signalling 
contributes to mucositis (a multifactorial process [13]), as TLR signalling is has been shown to be 
upregulated in response to increased bacterial ligands, resulting in further downstream upregulation of 
NFκB and pro-inflammatory cytokines [35]. 
Antimetabolite 5-Fluorouracil (5-FU), used to treat colorectal, breast and liver cancers, has been 
shown to be associated with changes to the intestinal microbiota. A study by von Bultzingslowen and 
colleagues in 2003 demonstrated that whilst there were no significant changes to levels of anaerobic 
bacteria in the small or large intestine following 5-FU administration (6 × 50 mg/kg) in Lewis rats, 
there was a shift in composition from predominantly Gram positive to Gram negative bacteria [52]. A 
later study by Stringer and colleagues in 2009 showed no significant findings, however peaks were 
observed following 5-FU administration (150 mg/kg, single dose) in E. coli at 48 h, Clostridium spp. at 
multiple time points, and Staphylococcus spp. at 24 h. Decreases were observed in Lactobacillus spp. at 
24 h and Enterococcus spp. at 2 h–48 h following treatment [22]. A combined 5-FU/Irinotecan 
regimen (irinotecan 50 mg/kg + 5-FU 50 mg/kg administered weekly for two weeks) elevated 
Clostridium cluster XI and Enterobacteriacaea, but to a lesser extent than the irinotecan regimen [49]. 
In clinical studies, changes to intestinal microbiota have also been demonstrated. In a study by  
van Vliet and colleagues in 2009, paediatric acute myeloid leukaemia patients receiving AML-97  
(i.e., high-dose cytarabine, daunorubicine, and etoposide [ADE I and ADE II]; amsacrine, high-dose 
cytarabine, and etoposide [MACE]; and mitoxantrone and high-dose cytarabine [MidAC]) were  
shown to have decreased intestinal microbial diversity using denaturing gradient gel electrophoresis  
(DGGE) [29]. Quantitative fluorescent in situ hybridisation (FISH) techniques were used to 
demonstrate significant decreases in total bacteria (p < 0.001), Bacteroides spp., Clostridium cluster 
XIVa, Faecalibacterium prausnitzii, and Bifidobacterium spp. (p < 0.004 for all) at both early and late 
time points following each cycle of chemotherapy [29]. Recovery was observed for both Clostridium 
XIVa and F. prausnitzii at 6 weeks following treatment. However, Bacteroides spp. and 
Bifidobacterium spp. were still lower in the end-of-treatment samples compared with the healthy 
controls [29]. This suggests that the intestinal microbiota may have the potential to be restored 
following chemotherapy, and the possibility of manipulation of the microbiota to promote healing 
following mucositis is an area requiring investigation. A study by Zwielehner and colleagues in 2011 
using molecular techniques to quantify bacteria in patients receiving varied chemotherapy regimens 
has shown a significant decrease in total microbiota (p = 0.037), similar to the van Vliet study in 2009. 
Similar decreases were also observed in Bifidobacterium spp., Lactobacillus and Clostridium  
cluster IV. Faecalibacterium prausnitzii also decreased dramatically, from 9% to zero following 
chemotherapy [53]. This study also demonstrated the appearance after chemotherapy of undetected 
bacteria prior to chemotherapy, which could suggest a potential risk to the patient of infection from 
these species.  
5.2. Effects of Chemotherapy on Mucins 
Mucins have been shown to be associated with mucositis [22,23,54–56]. Dark Agouti (DA) rat 
models of mucositis have been used to determine a significant association with mucin secretion and 
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expression [22,23]. Cavitated goblet cells (goblet cells which have released mucins through 
exocytosis) have been shown to significantly increase (p < 0.05) from 96 h to 144 h following 
irinotecan (200 mg/kg, single dose) treatment. Muc4 expression has also been shown to increase 
significantly (p < 0.05) in the jejunum compared to controls [23], which may suggest accelerated  
trans-membrane mucus production. 
In a study investigating 5-FU-induced mucositis (150 mg/kg, single dose), goblet cell numbers 
decreased significantly in the jejunum (p < 0.05), and the percentage of cavitated goblet cells increased 
significantly (p < 0.05) from 24 h to 72 h after treatment compared with controls [22]. Furthermore, a 
Wistar rat model of 5-FU-induced mucositis (5 × 50 mg/kg) caused a significant (p < 0.05) decrease in 
mucin levels compared to controls in the jejunum and colon [55], suggesting mucin expression was 
decreased. Mucin expression has also been shown to be significantly (p < 0.05) decreased in a Wag/Rij 
rat model of methotrexate (MTX) induced mucositis (2 × 10 mg/kg), with Muc 2 expression decreased 
significantly from 72 h to 44 h following MTX administration [56]. The findings of these studies 
suggest that mucins are released following chemotherapy, which may be due to effects of IL-1, 4, 6 
and 9, and TNF-α, also upregulated following chemotherapy. 
5.3. Effects of Chemotherapy on Pro-Inflammatory Cytokines 
Pro-inflammatory cytokines have long been held responsible for the tissue damage associated with 
mucositis [12,13,15,19,20,24,57]. Studies have shown significant increases in the expression of  
pro-inflammatory cytokines, with the key offenders TNF, IL-1β [13,19,20,57–59] IL-4 [60] and  
IL-6 [19,20,43,57,58]. In timeline studies of irinotecan by Logan and colleagues, both intestinal and 
serum levels of NFκB were significantly increased at 6 h–12 h following administration of irinotecan 
(p < 0.05). In the same study, intestinal and serum levels of TNF, IL-1β and IL-6 were also shown to 
be significantly increased at 6 h–24 h following irinotecan administration compared to controls  
(p < 0.05). The up-regulation of these cytokines is likely to result in the release of mucins from goblet 
cells, which may have further downstream effects on the intestinal microbiota, due to the subsequently 
altered environmental conditions in the intestinal mucosa and lumen.  
6. Relationships between Intestinal Microbiota, Mucins and Pro-Inflammatory Cytokines 
The timing of events in studies by Stringer and colleagues [23,47], and Logan and  
colleagues [19,20], supports the notion that these manifestations are connected. These studies have 
shown that percentage of cavitated goblet cells increased significantly at 24 h–72 h in the colon 
following irinotecan administration in the same animal model as the Logan studies [19,20,23]. They 
also showed a significant decrease in the expression of MUC2 at 24 h–72 h. In another study in the 
same animal model, changes to intestinal microbiota were observed, with a significant increase  
(p < 0.05) in E. coli at 24 h–48 h, and a significant decrease (p < 0.05) in Lactobacillus spp. at  
12 h–48 h [47]. When these findings are combined, they suggest that pro-inflammatory cytokines 
become activated through the activation of NFκB [13], subsequently feeding back to further amplify 
NFκB signalling, compounding the effects of the cytokines and subsequently the tissue damage. 
Intestinal microbiota also play a key role in the activation of cytokines through the up-regulation of 
TLR signalling (and subsequently NFκB signalling) (Figure 1). Pro-inflammatory cytokines can also 
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result in the rapid discharge of mucin stores in goblet cells [43], which may have led to the increased 
cavitation of goblet cells (Figure 1). The depletion of mucin stores in goblet cells will lead to subsequent 
effects on the mucus layer in the intestine, which in turn will affect the intestinal microbial ecology by 
reducing attachment sites and available nutrients (reducing the number of commensal bacteria, such as 
Lactobacillus spp., and allowing other aerotolerant species, such as E. coli, the capacity to proliferate) 
(Figure 1). These events are likely to be overarched by the increases in ROS and its downstream effects 
initiated soon after chemotherapy is administered. 
Figure 1. Relationships between mucins, microbiota and cytokines: the effects of chemotherapy. 
 
Chemotherapy causes a depletion in the mucus layer, usually protecting the epithelial surfaces of 
the intestine. This allows bacteria to penetrate and activate TLR signaling, which in turn activates 
NFκB signaling. Pro-inflammatory cytokines (IL-1, IL-6 and TNF) are activated by NFκB, and 
result in the rapid discharge of mucin stores from goblet cells. This rapid discharge can restore the 
mucus layer, but depletes mucin stores in goblet cells. Environmental conditions in the lumen are 
also altered, affecting the microbiota. 
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7. Future Directions 
Further investigations are required to fully elicit the intricate role of intestinal microbes in the 
development of gastrointestinal mucositis. Studies investigating the effects of ROS produced 
following administration of chemotherapy and the effects on microbiota, and investigating the intricate 
relationship between mucins and microbes in the development of mucositis following administration 
of chemotherapy agents should be carried out. The findings from such studies are likely to provide the 
level of evidence required to suggest some possible intervention targets to improve patient outcomes 
following cancer therapy. 
8. Conclusions 
Chemotherapy-induced mucositis is a complex process involving a number of tissue components 
and a moiety of signalling pathways. Intestinal microbiota has been shown to be altered following 
chemotherapy, and may therefore play a key role in the development of mucositis. Consequently, the 
intestinal microbiota, or components of the signalling systems activated by it, may be considered as 
potential targets for therapeutic intervention. 
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